A powerful new tool for the separation of charged species

4 Feb 2018

A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.

Traditional separation technology in these fields provides particle size or molar mass distributions as the final result. It is clear, however, that particle and molecular charge plays a primary role in many applications such as protein aggregation, polymer flocculation, particle agglomeration and in pharmaceutical formulations in general.

A powerful new tool for the separation of charged species
Postnova's new EAF4 system.

The new Postnova EAF2000 instrument using EAF4 technology opens a completely new way to a significantly better understanding of these phenomena by allowing the particle size or molar mass distributions to be further differentiated and transformed into charge distributions. This allows identifying charge heterogeneities, which may be present within the different size and molar mass fractions and will quickly help to aid research or establish more efficient product development processes.

The EAF2000 instrument works by combining the principle of electrical and flow field-flow fractionation (FFF) in one experiment. In flow FFF the molecules and particles are gently separated in an open channel which avoids any interaction with column packing material keeping aggregation and structures intact. The electrical field, either positive or negative, can now be applied during this separation to differentiate between differently charged species of the same size or molecular weight.

The new Postnova EAF2000 technology is also designed in such a way that it allows the determination of the electrophoretic mobility (or zeta-potential) of the separated analytes under investigation. This is a key new tool, particularly for protein research as existing techniques for zeta-potential are limited by concentration and are simple batch techniques giving just an average value for all components in the solution. The new EAF2000 can determine the zeta-potential of each individually separated component such as protein monomer and dimer (or higher aggregates) or antibody monomer and fragments/aggregates.

Early successes with the technology have been found in applications as diverse as the separation of a positively charged pharmaceutical protein formulation, determination of the difference in zeta-potential of protein monomer and dimer and the differentiation of charge on polymer latex particles.

There is the first chance to see this technology in action on 6 March at the 2nd Postnova FFF Seminar at the company's UK headquarters in Malvern (UK). Following the popularity of the first Postnova first seminar, an informative program of talks from eminent guest speakers, plus presentations from Postnova scientists has been assembled.

The free 2018 seminar has been designed to advance the attendees knowledge of applications and techniques in nanoscale characterisation. The seminar will be particularly useful to those interested in using FFF, Size Exclusion Chromatography (SEC/GPC) and Light Scattering/Viscometry (MALS/DLS), as well as those interested in how these techniques may be useful in their research.

With limited attendee spaces available please register now for this free Seminar by contacting Postnova Analytics at info.uk@postnova.com.

Read More

Related news

BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more 
One month on: medical cannabis is still taboo despite change in law

One month on: medical cannabis is still taboo despite change in law

11 Dec 2018

Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.

Read more 
EU FMD - time is running out!

EU FMD - time is running out!

13 Nov 2018

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

Read more 
Proprietary nasal delivery formulation of diazepam reaches NDA

Proprietary nasal delivery formulation of diazepam reaches NDA

7 Nov 2018

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

Read more 
DSCSA one-month countdown!

DSCSA one-month countdown!

30 Oct 2018

With only a month to go, it really is too late to start trying to develop an in-house solution.

Read more 
Global pharma set for strong year

Global pharma set for strong year

23 Oct 2018

Eight of the top ten pharma nations reporting improving market conditions.

Read more 
Generics companies to move away from little white pills

Generics companies to move away from "little white pills"

14 Oct 2018

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more